New Drug Launch and Commercialization Forum
2023year7month13 - 14RIO, by Yingfu ChuansiInfotransThe hosted 'Innovative Drugs Launch and Commercialization Forum' was successfully held in Shanghai. The forum aimed to explore the opportunities and challenges faced by the launch and commercialization of innovative drugs. Guests from biotech companies, pharmaceutical enterprises, industry associations, consulting firms, third-party commercialization platforms, investment institutions, law firms, etc., shared industry insights from their respective perspectives. The content covered topics such as the market environment and policies of innovative drugs, medical insurance negotiations, commercial health insurance, commercial layout, market promotion strategies, innovative drugs' full life cycle management plans, third-party platform empowerment of commercialization, drug exports, commercialization channels, and commercial intellectual property protection. It built a platform for industry communication and cooperation to help enhance China's commercialization capabilities of innovative drugs.
Frost & SullivanFrost & SullivanAs one of the forum's co-partners, Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, was invited to attend the event and delivered a speech on 'The Lifecycle Management Solution for Innovative Drugs'.
From left: affairs of the central government of BeiGene&Director of Policy, Mr. Honghao Shi, Senior Partner at Liu Shen Law Firm, Mr. Zongliang Zou Liangsheng Investment Partner Li Jia, Youdit BiotechnologyUltraDxfounder,CEODong Zengjun, Partner and Managing Director of Frost & Sullivan Greater China Region, Mao Hua
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua first shared the background of the development of the innovative drug industry. He pointed out that overall, the scale of China's pharmaceutical market has ranked second globally. Although there have been impacts from multiple rounds of price cuts in centralized procurement and medical insurance, considering favorable factors such as increasing disease burden, population aging, enhanced payment capabilities and diversification of payment methods, as well as an increase in innovative varieties, China's pharmaceutical market is still expected to continue growing in the future.
Currently, monoclonal antibodies, bispecific antibodies,ADCLarge molecule drugs such as antibody fusion proteins have become an important area of new drug research and development. Clinical trials of innovative therapies represented by cell therapy, gene therapy, nucleic acid drugs, and oncolytic viruses continue to increase. Recently3The annual proportion has reached4.1%. In terms of sub-sectors, given that both globally and in China, chronic disease burdens are on the rise year by year, Digestive and metabolic drugs, as well as anti-tumor drugs, occupy an important position in both global and Chinese markets.
Mao Hua stated that the entire lifecycle of a drug is dynamic and evolving. To achieve successful lifecycle management of innovative drugs, pharmaceutical companies need to focus on three winning strategies, namely:1) Efficient market access&Full-cycle price management;2Precise marketing strategies;3) Innovate business models. "Efficient market access and full-cycle price management will be the foundation of innovative drug lifecycle management. Precise marketing strategies can maximize the value of innovative drug products, reach patients more quickly. Business model innovation includes accelerating organizational structure optimization, retail format transformation, and digital marketing," Mao Hua further explained.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
2023Frost & Sullivan's New Investment Conference
